How did AIM's Q4 forecast compare to past surprises?

**AIM ImmunoTech's Q4 Forecast and Past Performance Analysis**

1. **Earnings Estimate and Surprise**: For Q4, analysts estimated an EPS of -$0.12, which was more optimistic than the company's actual EPS of -$0.06, a positive surprise of $0.06. In the previous quarter, AIM had beaten EPS by $0.09, leading to a 5.88% increase in the share price.

2. **Revenue Comparison**: The consensus for Q4 revenue was $35K, but AIM reported $17.5K, significantly lower than expected. In the prior quarter, revenue was overestimated by 400%, with reported revenue surpassing estimates by a substantial margin.

3. **Historical Performance**: AIM has shown variability in its financial performance. While there were positive EPS revisions in the recent period, indicating some optimism among analysts, the company's financial health score is reported as "weak performance" by InvestingPro.
4. **Market Reaction and Guidance**: The market has been influenced by AIM's clinical trial progress and potential partnerships with big pharma, which may influence future earnings expectations. However, the company's cash reserves and potential delisting from NYSE American present significant risks.

In conclusion, AIM ImmunoTech's Q4 performance reflects a mix of positive developments, such as clinical trial advancements and potential partnerships, and financial challenges, including low revenue and cash reserves. While the company has shown the ability to beat earnings expectations in certain quarters, the variability in performance and current financial constraints suggest caution for investors.